July 3, 2007 Now here’s an interesting product which might find all manner of niche applications. Next Safety has created a handheld pulmonary drug delivery device that delivers extremely high arterial levels of nicotine – with effects felt less than ten seconds after inhalation – and provides higher psychoactive effects than cigarettes or any other tobacco product on the market. It is expected that the device, which is roughly the size of a pack of cigarettes, will substantially increase success rates for those who wish to quit smoking due to its ability to accurately duplicate the delivery of nicotine from tobacco smoke. Additionally, by delivering a high percentage of nicotine to the bloodstream, the use of the device is expected to cost less than 30 percent of the equivalent cost of cigarettes. We guess the same would be true for any other substances people smoked too. Hmmmm Could this be used indoors to beat the smoking bans implemented this week in the U.K. and Australia?
The unit will be used in much the same way as current inhalers. Nicotine is supplied by replaceable cartridges that contain nicotine and electronically stored information to ensure safe dosing. Battery powered circuitry monitors the system to create and deliver an aerosol to the lungs at the optimal point during inhalation. The aerosol is delivered through a mouthpiece connected to the system by a flexible hose.
Initially, the unit will be provided to unregulated global markets with availability in other areas following regulatory compliance. With 2006 tobacco sales of around US$218 billion in developed countries and more than one billion smokers globally, Next Safety, Inc. anticipates production volumes will reach more than one million units monthly in the first quarter of 2008. Primary manufacturing capacity will be provided through contract-manufacturing firms and a significant expansion of Next Safety’s West Jefferson, NC facility.
“North Carolina has long been known as ‘Tobacco Road.’ These days Tobacco Road is known for technology. We believe that Next Safety’s technology will end the tobacco use epidemic,” said C. Eric Hunter, CEO and founder of Next Safety, Inc. “If I was a banker engaged in a private equity transaction related to tobacco, a proposed deal in Europe comes to mind immediately, these results would make me take a step back and evaluate the transaction in light of this new information.”
In addition to nicotine, Next Safety will soon launch drug delivery tests utilizing its pulmonary drug delivery method and devices that will include antibiotics (tobramycin), anti-emetics (promethazine), bronchodilators (albuterol), and narcotics (morphine).
Next Safety now brings the same innovative approach to the science of pulmonary drug delivery and nicotine replacement.